面向早期类风湿关节炎甲氨蝶呤响应个体化预测:药物基因组学驱动的机器学习方法
本研究利用643例欧洲血统早期类风湿关节炎(RA)患者的临床与基因组数据,将160个单核苷酸多态性(SNP)与年龄、性别、吸烟、类风湿因子、基线DAS28评分结合,训练并验证监督机器学习模型预测甲氨蝶呤单药治疗3个月时EULAR应答。验证队列预测准确率76%(P=0.05),敏感度72%、特异度77%,作者认为药物基因组生物标志物联合基线DAS28评分有助于预测甲氨蝶呤响应。
要点
- 训练队列中联合160个SNP与临床变量的模型预测3个月EULAR应答的AUC为0.84(P=0.05)。
- 验证队列预测准确率76%(P=0.05),敏感度72%、特异度77%。
- rs12446816、rs13385025、rs113798271及ATIC rs2372536变量重要性均高于60.0,与基线DAS28同为最重要预测因子。
核心结论
- 药物基因组生物标志物联合基线DAS28评分可能有助于预测早期RA患者对甲氨蝶呤的响应。
- 将机器学习应用于治疗响应预测有望指导有效的RA治疗选择,包括及时升级RA治疗。
研究设计与样本
- 研究纳入643例欧洲血统早期RA患者,平均年龄54岁、女性占70%,分为训练队列336例与验证队列307例。
- 基因组数据包括160个既往与RA或甲氨蝶呤代谢相关的SNP,临床变量包括年龄、性别、吸烟、类风湿因子和基线DAS28评分。
- 甲氨蝶呤单药治疗响应定义为3个月随访时EULAR应答标准中的良好或中等应答。
- 监督机器学习方法在训练队列中以5次重复、10折交叉验证进行训练,并在独立验证队列中验证预测性能。
主要发现
- 训练队列中联合年龄、性别、吸烟、类风湿因子、基线DAS28评分和160个SNP的监督机器学习方法预测3个月EULAR应答的受试者工作特征曲线下面积为0.84(P=0.05)。
- 验证队列预测准确率为76%(P=0.05),敏感度72%、特异度77%。
- 基因间区SNP rs12446816、rs13385025、rs113798271和ATIC rs2372536的变量重要性均高于60.0,与基线DAS28评分同属甲氨蝶呤响应的最重要预测因子。
关键数值与推荐
- 响应定义采用EULAR应答标准,于3个月随访时判定为良好或中等应答。
- 训练队列预测性能AUC为0.84(P=0.05)。
- 验证队列预测准确率76%(P=0.05),敏感度72%、特异度77%。
- rs12446816、rs13385025、rs113798271和ATIC rs2372536变量重要性均高于60.0。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the ability of machine learning (ML) approaches with clinical and genomic biomarkers to predict methotrexate treatment response in patients with early rheumatoid arthritis (RA). METHODS: Demographic, clinical, and genomic data from 643 patients of European ancestry with early RA (mean age 54 years; 70% female) subdivided into a training (n = 336) and validation cohort (n = 307) were used. The genomic data comprised 160 single-nucleotide polymorphisms (SNPs) previously associated with RA or methotrexate metabolism. Response to methotrexate monotherapy was defined as good or moderate by the European Alliance of Associations for Rheumatology (EULAR) response criteria at the 3-month follow-up. Supervised ML methods were trained with 5 repeats and 10-fold cross-validation using the training cohort. Prediction performance was validated in the independent validation cohort. RESULTS: Supervised ML methods combining age, sex, smoking, rheumatoid factor, baseline Disease Activity Score in 28 joints (DAS28) scores and 160 SNPs predicted EULAR response at 3 months with the area under the receiver operating curve of 0.84 (P = 0.05) in the training cohort and achieved a prediction accuracy of 76% (P = 0.05) in the validation cohort (sensitivity 72%, specificity 77%). Intergenic SNPs rs12446816, rs13385025, rs113798271, and ATIC (rs2372536) had variable importance above 60.0 and along with baseline DAS28 scores were among the top predictors of methotrexate response. CONCLUSION: Pharmacogenomic biomarkers combined with baseline DAS28 scores can be useful in predicting response to methotrexate in patients with early RA. Applying ML to predict treatment response holds promise for guiding effective RA treatment choices, including timely escalation of RA therapies.
引用
- Myasoedova E, Athreya AP, Crowson CS, et al. Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A Pharmacogenomics-Driven Machine Learning Approach. Arthritis Care Res (Hoboken). 2022. PMID: 34902228. doi:10.1002/acr.24834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。